Cargando…

Dose Selection in a Pandemic: A Framework Informed by the FDA Animal Rule

Detalles Bibliográficos
Autores principales:	Wu, Kunyi, Bergman, Kimberly L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Perspectives
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7753767/ https://www.ncbi.nlm.nih.gov/pubmed/33201590 http://dx.doi.org/10.1111/cts.12936

Ejemplares similares

First vaccine approval under the FDA Animal Rule
por: Beasley, David W C, et al.
Publicado: (2016)

The FDA’s Regulatory Framework for Chimeric Antigen Receptor‐T Cell Therapies
por: Marks, Peter
Publicado: (2019)

Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK
por: Wagner, C, et al.
Publicado: (2015)

Animal‐to‐Human Dose Translation of Obiltoxaximab for Treatment of Inhalational Anthrax Under the US FDA Animal Rule
por: Nagy, CF, et al.
Publicado: (2016)

FDA Experience with Medical Countermeasures under the Animal Rule
por: Aebersold, Paul
Publicado: (2012)

Broadening the reach of the FDA Sentinel system: A roadmap for integrating electronic health record data in a causal analysis framework
por: Desai, Rishi J., et al.
Publicado: (2021)

Challenging the FDA Black Box Warning for High Aspirin Dose With Ticagrelor in Patients With Diabetes
por: DiNicolantonio, James J., et al.
Publicado: (2013)

Industrial Perspective on the Benefits Realized From the FDA’s Model‐Informed Drug Development Paired Meeting Pilot Program
por: Galluppi, Gerald R., et al.
Publicado: (2021)

The current landscape of the FDA approved companion diagnostics
por: Jørgensen, Jan Trøst
Publicado: (2021)

Ten simple rules for women principal investigators during a pandemic
por: Kreeger, Pamela K., et al.
Publicado: (2020)

FDA perspectives on potential microarray-based clinical diagnostics
por: Težak, Živana, et al.
Publicado: (2006)

Testing the theory of immune selection in cancers that break the rules of transplantation
por: Fassati, Ariberto, et al.
Publicado: (2009)

A Framework for Modeling Emerging Diseases to Inform Management
por: Russell, Robin E., et al.
Publicado: (2017)

The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA.
por: Olivier, Timothée, et al.
Publicado: (2022)

FDA draft guidance to improve clinical trial diversity: Opportunities for pharmacoepidemiology
por: Russell, Elizabeth S., et al.
Publicado: (2023)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

Toward a unified information framework for cell atlas assembly
por: Chen, Sijie, et al.
Publicado: (2021)

Translational research of one dynamic hip screw system—from the SCI to the FDA
por: Kao, Hung-Chan, et al.
Publicado: (2016)

The FDA-Approved Essure Device Counseling Order Fails to Promote Patient Empowerment
por: Gunn, Christine M., et al.
Publicado: (2019)

FDA oversight of NSIGHT genomic research: the need for an integrated systems approach to regulation
por: Milko, Laura V., et al.
Publicado: (2019)

A framework to guide dose & regimen strategy for clinical drug development
por: Sander, Oliver, et al.
Publicado: (2021)

The Sharing Experimental Animal Resources, Coordinating Holdings (SEARCH) Framework: Encouraging Reduction, Replacement, and Refinement in Animal Research
por: Morrissey, Bethny, et al.
Publicado: (2017)

Model Informed Drug Development: Collaboration Through A Common Framework
por: Anziano, Richard J., et al.
Publicado: (2020)

Overview of the Side-Effects of FDA- and/or EMA-Approved Targeted Therapies for the Treatment of Hematological Malignancies
por: Constantinescu, Catalin, et al.
Publicado: (2020)

FDA position statement “Early Alzheimer's disease: Developing drugs for treatment, Guidance for Industry”
por: Sabbagh, Marwan N., et al.
Publicado: (2019)

Pharmacogenetic Labeling of FDA-Approved Drugs: A Regulatory Retrospective
por: Drozda, Katarzyna, et al.
Publicado: (2018)

Mechanistic Oral Absorption Modeling and Simulation for Formulation Development and Bioequivalence Evaluation: Report of an FDA Public Workshop
por: Zhang, X, et al.
Publicado: (2017)

The Coming of Age of AI/ML in Drug Discovery, Development, Clinical Testing, and Manufacturing: The FDA Perspectives
por: Niazi, Sarfaraz K
Publicado: (2023)

Understanding the new FDA pregnancy and lactation labeling rules()
por: Blattner, Collin M., et al.
Publicado: (2016)

Pandemic prevention and unsustainable animal-based consumption
por: Sandhu, Harman S, et al.
Publicado: (2021)

The proposed rule of the FDA banning menthol as a characterizing flavor
por: Romeo-Stuppy, Kelsey
Publicado: (2022)

Ten simple rules to ruin a collaborative environment
por: Lawrence-Dill, Carolyn J., et al.
Publicado: (2022)

Impact of recent FDA ruling on testosterone replacement therapy (TRT)
por: Metzger, Sarita O., et al.
Publicado: (2016)

A Real‐World Evidence Framework for Optimizing Dosing in All Patients With COVID‐19
por: Peck, Richard W., et al.
Publicado: (2020)

FDA Advisory Meeting Clinical Pharmacology Review Utilizes a Quantitative Systems Pharmacology (QSP) Model: A Watershed Moment?
por: Peterson, MC, et al.
Publicado: (2015)

The Soil Microbiota Recovery in the Agroecosystem: Minimal Information and a New Framework for Sustainable Agriculture
por: Bergna, Alessandro, et al.
Publicado: (2022)

Modeling to inform economy‐wide pandemic policy: Bringing epidemiologists and economists together
por: Darden, Michael E., et al.
Publicado: (2022)

Ten simple rules for creating a scientific web application
por: Burnett, Jessica L., et al.
Publicado: (2021)

Farm animal genetic resources and the COVID-19 pandemic
por: Gandini, Gustavo, et al.
Publicado: (2021)

Mendelian Randomization Studies Promise to Shorten the Journey to FDA Approval
por: Roberts, Robert
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_03srr9t041oevovck9mk7ig85n